生物/向合成DMARD与手部关节形发病率较低的关联在类风湿性关节炎中:一个横截面的现实世界研究
Ying Yang1, Jian-Zi Lin1, Yao-Wei Zou1
1Department of Rheumatology and Immunology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yan Jiang West Road, Guangzhou 510120, China.
Medicina (Kaunas, Lithuania)
|February 27, 2026
概括
生物和向合成修饰疾病的抗风湿药物 (b/tsDMARDs) 显著降低了类风湿性关节炎 (RA) 患者的手关节形. 这一发现凸显了b/tsDMARDs在维护手部功能和改善RA患者生活质量的有效性.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 整形外科 整形外科 整形外科
背景情况:
- 类风湿性关节炎 (RA) 经常导致手关节形,严重影响患者的生活质量.
- 了解影响变形患病率的因素对于有效的RA管理至关重要.
研究的目的:
- 调查生物和向合成修饰疾病的抗风湿药物 (b/tsDMARDs) 与RA患者的手关节形之间的关联.
- 评估b/tsDMARDs对特定手关节形的患病率的影响.
主要方法:
- 对1083名RA患者 (2019-2024) 的截面分析.
- 手关节形是由28个特定的手关节 (MCP,PIP,DIP) 的存在来定义的.
- 多变量逻辑回归和倾向得分匹配用于分析b/tsDMARDs治疗与变形的关联.
主要成果:
- 25.4%的RA患者出现了手关节形,其中近端间关节 (PIP) 受到影响最多.
- 17.4%的患者使用了生物和向合成修饰疾病的抗风湿药物 (b/tsDMARDs).
- 倾向性得分匹配显示,与传统治疗相比,接受b/tsDMARDs的患者的变形患病率显著降低 (27.1%与61.7%相比) (p < 0.001).
结论:
- 生物和向合成疾病修饰性抗风湿药物 (b/tsDMARDs) 的使用独立地与RA中手关节形的发病率较低有关.
- 这些发现支持b/tsDMARDs在缓解结构损伤和在类风湿性关节炎中保持手部功能方面的作用.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
658
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
658
Genome-wide Association Studies-GWAS
16.0K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
16.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
577
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
577
Rheumatic Heart Disease III: Medical Management
420
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
420
The JAK-STAT Signaling Pathway
13.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.4K


